TITLE

Pipeline

PUB. DATE
June 2009
SOURCE
Pharmaceutical Representative;Jun2009, Vol. 39 Issue 6, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents several clinical trials of different drugs in the U.S. Sunitinib monotherapy, which is designed to treat advanced breast cancer, was discontinued due to visibility of futility. Another is Brochitol from Pharmaxis Ltd., which has received positive results and completed the international Phase III trial. Meanwhile, SparVax, a protective antigen anthrax vaccine from PharmAthene Inc. has completed its second trial and has shown no significant difference with BioThrax.
ACCESSION #
40521964

 

Related Articles

  • Opinion: GlaxoSmithKline: Tykerb steps up challenge to Herceptin.  // PharmaWatch: Cancer;Jun2008, Vol. 7 Issue 6, p7 

    The author reflects on the Phase III trial comparing Tykerb and Herceptin neoadjuvant therapies by GlaxoSmithKline in Europe. According to the author, the tests would analyze the potentiality of the two newly introduced drugs. The author contends that the Phase III trials would favor Tykerb...

  • Pharmaxis Hits the Mark in Phase III Cystic Fibrosis Trial. Hollingsworth, Catherine // BioWorld International;5/6/2009, Vol. 14 Issue 18, p5 

    The article reports on clinical trials for the cystic fibrosis drug of Pharmaxis. Users of Bronchitol showed significant improvements in lung functions from baseline of 6.6% as compared to placebo. Lung function got better at week six and remained so until week 26. The drug is intended to reduce...

  • Cytokinetics initiates Phase I/II metastatic breast cancer trial.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p10 

    The article provides information about Cytokinetics Inc.'s sponsored clinical trial in breast cancer patients. Cytokinetics initiates Phase I/II clinical trials designed to evaluate ispinesib monotherapy as a first-line treatment in locally advanced or metastatic breast cancer. Objectives of the...

  • GlaxoSmithKline reports positive results for cancer combination therapy.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p11 

    The article reports on the results of GlaxoSmithKline's Phase II clinical trial on its oral kinase inhibitor, Tykerb. In the study involving 49 patients, the combination of Tykerb plus capecitabine showed a reduction in breast cancer that had spread to the brain. Specifically, 20% of the 49...

  • COMPANY SPOTLIGHT - Eisai.  // PharmaWatch: Monthly Review;Jul2010, Vol. 9 Issue 7, p51 

    The article profiles the Japanese pharmaceutical company Eisai Co. Ltd. It outlines the company's business description which focused on developing, manufacturing and selling of pharmaceuticals. It provides updates on the result of the company's Phase III study of its eribulin mesylate, an...

  • Immutep presents encouraging results from breast cancer study.  // PharmaWatch: Cancer;Jan2008, Vol. 7 Issue 1, p9 

    The article reports on the results of a study conducted by Immutep for its ImmuFact IMP321 administered in patients with metastatic breast cancer. The compound is a potent natural human immunostimulatory factor designed to amplify the T-cell immune response. It can be used as an...

  • Geron initiates enrollment in Phase I/II breast cancer trial.  // PharmaWatch: Cancer;Sep2008, Vol. 7 Issue 9, p10 

    The article reports on the Phase I/II clinical trial conducted by Geron Corp. which aims to assess the effectiveness of its telomerase inhibitor drug GRN163L in treating breast cancer. The study will also focus on evaluating the response of the drug when associated with paclitaxel/bevacizumab...

  • Advances in using PARP inhibitors to treat cancer.  // BMC Medicine;2012, Vol. 10 Issue 1, p25 

    The article presents a study on advances in using poly (ADP-ribose) polymerase (PARP) inhibitors to treat cancer. Several PARP inhibitors are in clinical development; as a whole, these agents have generated considerable interest because of their potential clinical activity for patients whose...

  • European Journal of Surgical Oncology.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article offers information on the publication of trial results for the drug, Restore-2 which is used in Cytori breast reconstruction cell therapy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics